MYCN and neuroblastoma: Interestingly, when studied in patient derived xenograft models of MYCN-amplified neuroblastoma, venetoclax alone had modest activity however, when combined with the Aurora A kinase inhibitor, alisertib, activity was dramatic with all tumors achieving complete and sustained regression [93].